Study Spot
Customized learning paths based on interests
In Children's Oncology Group T-ALL trials conducted from 2000 to 2005, for such patients, the overall survival rate at 4 years was around 80%. The 4-year DFS rate for T-ALL patients who received nelarabine was 88.9%; for patients who did not receive nelarabine, the 4-year DFS was 83.3% (P = . 0332).
Latest figures show that the 5-year survival rate for all subtypes of leukemia is 61.4 percent. A 5-year survival rate looks at how many people are still alive 5 years after their diagnosis. Leukemia is most common in people aged over 55, with the median age of diagnosis being 66.Latest figures show that the 5-year survival rate for all subtypes of leukemia is 61.4 percent. A 5-year survival rate looks at how many people are still alive 5 years after their diagnosis. Leukemia is most common in people aged over 55, with the median age of diagnosis being 66.